摘要
【目的】探讨吡格列酮对急性冠脉综合征（ACS）合并2型糖尿病患者血浆淀粉样蛋白A（SAA）、C反应蛋白（CRP）及白介素1β（IL-1β）水平的影响及其非降糖作用。[方法]69例合并2型糖尿病的急性冠脉综合征患者随机分为两组，实验组在不停用已有降糖药的基础上加用吡格列酮30mg／d，分两次服。对照组在已有降糖药的基础上加用安慰剂。用酶联免疫吸附实验（ELISA）的方法分析两组患者在干预前后的血浆SAA和IL-1β水平；颗粒增强的免疫透射比浊法测定血浆CRP水平。【结果】实验组患者在干预1周后血浆SAA和IL-1β水平下降差异有显著性（P〈0．05），而CRP有下降趋势但无统计学意义（P〉0．05）。对照组在干预前后血浆SAA、CRP和IL-1β水平均无明显变化（P〉0．05）。两组干预前后血糖和胰岛素水平差异均无显著性（P〉0．05）。【结论】吡格列酮能降低急性冠脉综合征合并2型糖尿病患者的血SAA和IL-1β水平，其抑制SAA和IL—1β水平的作用不依赖其代谢调节作用。
[Objective]To study the effects of pioglitazone on plasma SAA, C-reactive protein（CRP） and IL-1β levels in acute coronary syndrome（ACS） with type 2 diabetes patients. [Methods]A total of 69 subjects suffering from ACS with type 2 diabetes mellitus were investigated by a cross-sectional study. All patients were randomized into two groups. The experimental group received hypoglycemic agents plus pioglitazone 15 mg twice daily. The control group received hypoglycemic agents plus placebo. The levels of plasma SAA and IL-1β were measured by enzyme-linked immunoadsordent assay （ELISA）, while ultra-sensitive CRP was measured by particle enhanced immunoturbidimetry assay. All patients performed angiography. [Results]There was significant difference between levels of plasma SAA and IL-1β before and after pioglitazone treatment（ P 〈0.05）. No significant difference was found between levels of plasma CRP before and after pioglitazone treatment （ P 〉0.05）. In the control group, there was no difference in the levels of three inflammatory mediators between before and after treatment （ P 〉0.05）. Pioglitazone had not affected the levels of glucose and insulin （ P 〉0.05）. [Conclusion]Pioglitazone can decrease the levels of plasma SAA and IL-1β in ACS with type 2 diabetes mellitus. The effect of pioglitazone for reducing the levels of plasma SAA and IL-1β in ACS with type 2 diabetes mellitus is independent of decreasing the levels of glucose and insulin.
出处
《医学临床研究》
CAS
2009年第3期381-383,共3页
Journal of Clinical Research
基金
湖南省卫生厅资助课题（编号B2004103）
